TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of watering of the eye subjective evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the degree of localized conjunctival hyperemia involving the nasal quadrant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial complex activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Growth Factor Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With AEs, SAEs, AEs Leading to Discontinuation and Deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival Rate (PFSR) at 24 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival Rate (PFSR) at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Target-to-background ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of enthesopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elder abuse prevalence
Endpoint domain: Mortality/survival
Primary endpoint: elder abuse incidence
Endpoint domain: Mortality/survival
Primary endpoint: Change in cognition from baseline at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global clinical impression of change from baseline at week 24
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac disease knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in session quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of planned session conducted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in satisfaction of trained health workers with training and intervention implementation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Best corrected visual acuity in treated eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported adherence to self-care regimens
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Derivation of induced pluripotent stem (iPS) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy yield from walnuts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in baseline PCL (PTSD) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in baseline Military to Civilian Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in baseline Social Support Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in baseline suicidality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pocket Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of Amnisure vs conventional testing for PPROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability change from baseline in laboratory assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability change from baseline in electrocardiogram (ECG) reading
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability change from baseline in fluid intake
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability change from baseline in electrolytes
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Tolerability change from baseline in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Expression of Cell Cycle-related Proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in self-ratings regarding quality of life throughout gender-affirming hormone treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in self-ratings regarding psychological well-being and psychiatric Symptoms throughout gender-affirming hormone treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes in self-ratings regarding gender congruence throughout gender-affirming hormone treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: degree of fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body site temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum reduction in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With HBV DNA Levels ≥ 20 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severity of Retinopathy of Prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Pain visual analogue scale (VAS) score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swelling change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein analysis from cervical mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival at 6 Month
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of partners that uptake HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reduction of biomarkers of exposure and toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of the ELLIPTA Inhaler
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in International Restless Legs Syndrome Rating Scale (IRLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of ICCU/all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Amplitude of muscle activation in mV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency pattern of muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Success of Improvement in NYHA Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance Goal for Effective Orifice Area (EOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete Clinical Response (CCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of serious adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects discontinuing the study due to intolerability of cetuximab
Endpoint domain: Adverse events/effects
Primary endpoint: Ki-67 reduction below 15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrence of instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity score based on a 28 joint count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite scoring of unaided distance and near vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual astigmatism evaluation by Subjective Refraction and autorefraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite quality score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Episode cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Utilization of acute and specialty care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: proportion of maternal desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy in assessment of local tumor proliferation and lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy in assessment of tumor regression following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prognostic information from biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major neurological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentration of fevipiprant by AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of fevipiprant by AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of fevipiprant by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of fevipiprant by AUC0-68h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotype Opsonization Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients reporting Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Limb Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 28-Day Average DVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epileptiform activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seroconversion against SARS-CoV2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the implant probing depth (IPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multifidus Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-week continuous quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in the INCAT Disability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Exclusive breastfeeding prevalence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ability to suture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ionized magnesium (whole blood)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total magnesium in serum and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of TKI258
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indexed Cardiac Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time from emergency admission to surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavioral Change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Bruininks-Oseretsky Test of Motor Proficiency Second Edition Brief Form (BOT-2 SF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Function and Occupational Routines Scale (EFORTS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceptions of training program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of unique genetic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Global Rating Scale Component of the Intraoperative Assessment Tool (GOALS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: maximum tolerated dose of JNJ-26483327
Endpoint domain: Adverse events/effects
Primary endpoint: safety (effects on the body)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression-change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antimicrobial effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in grief symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in symptoms of Major Depressive Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximal Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Interstitial glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Luteinizing Hormone (LH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Regional oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain inflammation measured via [18F] GE-180 PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anatomical, structural, and functional changes in the brain via MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Systemic inflammatory factors affecting ALS progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wound Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Drug-related Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of all-cause mortality at 30 days follow-up
Endpoint domain: Mortality/survival
Primary endpoint: anatomical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Geometric Mean Concentrations (GMCs) of Anti-Protein D, Anti-Protein E, Anti-type IV Pili Subunit, and Anti-ubiquitous Surface Protein A2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Adverse Drug Reaction (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Showing Response to the Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 4 or Higher Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from atrial arrhythmias (>30s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident number of HIV Infections
Endpoint domain: Mortality/survival
Primary endpoint: Number of cough efforts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance of the WATCHMAN LAA Closure device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ventral-striatal activation during a reward task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Full Stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Induction of T cells that penetrate into breast cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resting state networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in 18FDG PET scan signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stool Microbiota Composition Change During Prebiotic Only Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stool Microbiota Composition Change During Synbiotic Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recommended Phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment Related Adverse Event, including Abnormal Laboratory Events
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived isolation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Perceived mastery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Achievement motives
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Complete response in acute phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response in delayed phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
Endpoint domain: Adverse events/effects
Primary endpoint: % Embryos with aneuploidies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Calcineurin inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual analogue scale at 30 minutes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: knowledge of oral prevention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of diclofenac in reducing pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major erythroid response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change from Baseline in Serum TTR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 24-hour Serum Cortisol Weighted Mean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of repeat dilations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Occurrence of Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative Muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Veno-occlusive Disease (VOD)-Free Survival by Day +30
Endpoint domain: Mortality/survival
Primary endpoint: Esthetic effect
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Subjects With no Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Heavy Drinking Days Per Week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CRC morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Catheter-associated Urinary Tract Infection
Endpoint domain: Adverse events/effects
Primary endpoint: 6 months and one year survival after lung transplant
Endpoint domain: Mortality/survival
Primary endpoint: Change in area under the plasma concentration time curves for probe drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical excitability changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of high on-treatment platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Canadian Occupational Performance Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Performance Quality Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number and percentage of patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of platelet toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Yale Preoperative Anxiety Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Patients Alive and Progression-free 6 Months After Inclusion
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Concentration (Cmax) of LY2157299
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Concentration (tmax) of LY2157299
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes